PDCD1 and neoplasm: In anti-PD-1 monotherapy, several clinical and preclinical studies have concluded that infiltrating and circulating CD4+ and CD8+ T cells are important in the anti-tumor effect of ICIs (Supplementary Table S2), with major anti-tumor responses biased to the CD8+ T-cell effects.